| First Author | Pomeroy C | Year | 1998 |
| Journal | J Lab Clin Med | Volume | 132 |
| Issue | 2 | Pages | 124-33 |
| PubMed ID | 9708573 | Mgi Jnum | J:49105 |
| Mgi Id | MGI:1276675 | Doi | 10.1016/s0022-2143(98)90007-5 |
| Citation | Pomeroy C, et al. (1998) Role of interferon-gamma in murine cytomegalovirus infection. J Lab Clin Med 132(2):124-33 |
| abstractText | Interferon-gamma has well-documented antiviral and immunomodulatory activity, but its role in the control of cytomegalovirus (CMV) infection is not well studied. In a mouse model of murine CMV (MCMV) disease, interferon-gamma concentrations in serum but not in bronchoalveolar lavage fluid increased in response to viral infection. Serum interferon-gamma levels peaked at day 2 in the relatively resistant C57BL/6 mice, and, in contrast, did not peak until day 6 in susceptible BALB/c mice. Mice genetically lacking interferon-gamma (GKO) were more susceptible to MCMV, although strain differences persisted, with C57BL/6 GKO mice experiencing less severe MCMV disease than BALB/c GKO mice. Treatment of MCMV-infected BALB/c mice with exogenous interferon-gamma starting 2 days after viral infection had a modest protective effect at lower interferon-gamma doses (10(4) units), but interferon-gamma therapy markedly increased morbidity and mortality when higher doses (10(5) units) were used. We conclude that interferon-gamma plays a significant role in host response to MCMV and that the cytokine has dose- and time-dependent beneficial and adverse effects. |
